This is a competing continuation for a grant entitled ?Biomarkers of Cognitive Decline Among Normal Individuals: The BIOCARD Cohort? (FOA: PAR-18-296). This study, known as the BIOCARD study, is a longitudinal, observational study of 349 individuals who were cognitively normal and primarily middle aged (mean age=57.1) at enrollment. By design, two-thirds had a family history of Alzheimer?s disease (AD). The primary goal was to follow individuals from normal cognition to mild cognitive impairment (MCI) or dementia, so that it would be possible to identify biomarkers that predicted progression. The BIOCARD study is in a unique position to examine the ?preclinical? phase of AD, since the participants: (1) have been followed for up to 27 years (mean follow-up = 15.2 yrs.), (2) are continuing through the period of accelerating risk, and (3) 64 of those alive have MCI or dementia. Our overall objectives are to further advance the study of preclinical AD by: (1) clarifying the pattern and rate of change in AD biomarkers (including those based on CSF, blood, MRI, and PET imaging) and cognition; the biomarkers to be studied include several promising novel biomarkers derived from blood, CSF and brain imaging. (2) maximizing our data by working collaboratively with several research groups who have comparable data, and (3) providing a publicly accessible data, brain scans, and biological specimens, for researchers in the field. The long duration of follow-up for the cohort is based on the fact that the study was established in 1995 by investigators in the intramural program of the NIH. The study was stopped for administrative purposes in 2005. Our investigative team was funded in July 2009 to re-enroll the participants and re-initiate longitudinal data collection. Longitudinal follow-up was continued with our grant renewal in 2014. With this application, we are requesting funds to continue the longitudinal assessments which include: clinical and cognitive assessments, CSF, blood, MRI scans, and amyloid PET (using [11-C] PiB) and to initiate Tau PET (using [18 F] MK-6240), in the participants who remain cognitively normal (n=198, mean age = 70.9). We are also proposing to recruit an additional 150 subjects to increase the diversity of the participants and to expand the number of middle age subjects who can be followed with state-of-art- techniques. The rich data to be acquired will provide continued insights into the preclinical phase of AD.

Public Health Relevance

The overarching goal of this research is to improve our understanding of the earliest stages at which Alzheimer?s disease develops. In this study we are examining a range of biomarkers that may help identify those who are cognitively normal but at high risk of developing cognitive decline. It is hoped that this will lead to a better understanding of the disease and to effective interventions that may prevent progression.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AG033655-12
Application #
10003132
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Hsiao, John
Project Start
2009-07-01
Project End
2024-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Neurology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Sathe, Gajanan; Na, Chan Hyun; Renuse, Santosh et al. (2018) Phosphotyrosine profiling of human cerebrospinal fluid. Clin Proteomics 15:29
Hinkle, Jared T; Perepezko, Kate; Bakker, Catherine C et al. (2018) Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. Int J Geriatr Psychiatry 33:e131-e139
Chan, Carol K; Soldan, Anja; Pettigrew, Corinne et al. (2018) Depressive symptoms in relation to clinical symptom onset of mild cognitive impairment. Int Psychogeriatr :1-9
Albert, Marilyn; Zhu, Yuxin; Moghekar, Abhay et al. (2018) Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years. Brain :
Blauwendraat, Cornelis; Pletnikova, Olga; Geiger, Joshua T et al. (2018) Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol Aging :
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998
Soldan, Anja; Pettigrew, Corinne; Albert, Marilyn (2018) Evaluating Cognitive Reserve Through the Prism of Preclinical Alzheimer Disease. Psychiatr Clin North Am 41:65-77
Chiang, Angie C A; Fowler, Stephanie W; Reddy, Rohit et al. (2018) Discrete Pools of Oligomeric Amyloid-? Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol 188:739-756
Pettigrew, Corinne; Soldan, Anja; Sloane, Kelly et al. (2017) Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. Neuroimage Clin 16:439-446

Showing the most recent 10 out of 52 publications